Projet MMBio (Horizon 2020, appel à projets 2016)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : CLOSED

MMbio will bridge the classically separate disciplines of Chemistry and Biology by assembling leading experts from academia and non-academic partners (industry, technology transfer & science communication) to bring about systems designed to interfere therapeutically with gene expression in living cells. Expertise in nucleic acid synthesis, its molecular recognition and chemical reactivity is combined with drug delivery, cellular biology and experimental medicine. This project represents a concerted effort to make use of a basic and quantitative understanding of chemical interactions to develop and deliver oligonucleotide molecules of utility for therapy. Our chemical biology approach to this field is ambitious in its breadth and represents a unqiues opportunity to educate young scientists across sectorial and disciplinary barriers. Training will naturally encompass a wide range of skills, requiring a joint effort of chemists and biologists to introduce young researchers in a structured way to and array of research methodologies that no single research grouping could provide. The incorporation of early-stage and later stag ebiotechnology enterprises ensures that commercialisation of methodologies as well as the drug development process is covered in this ITN. We hope that MMBio will train scientists able to understand both the biological problem and the chemistry that holds the possible solution and develop original experimental approaches to stimulate European academic and commercial success in this area.

Mots clés : chemical biology, bioorganic chemistry, nucleic acid, drug, transfection, therapy, antisense

Participants :
- Synthena ag (Suisse) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Cambridge (Royaume-Uni) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 546575.76 €
- Cambridge entreprise limited (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ananas nanotech (Italie) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Ghent University (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 250560.0 €
- Oligomer sciences ab (Suède) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Goethe University Frankfurt (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- University of Padua (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 516122.64 €
- Karolinska Institutet (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 263659.32 €
- Sp process development ab (Suède) — Partner, beneficiary, Recherche, subvention : 29295.48 €
- University of Bern (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 265226.76 €
- AstraZeneca (Sweden) (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 263659.32 €
- Stockholm County Council (Suède) — Partner, beneficiary, Organismes publics (hors enseignement & recherche), subvention : 263659.32 €
- RISE Research Institutes of Sweden (Suède) — Partner, beneficiary, Recherche, subvention : 234363.84 €
- University of Sheffield (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 546575.76 €
- Alzheimer's Society (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- AstraZeneca (United Kingdom) (Royaume-Uni) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 273287.88 €
- University of Turku (Finlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 269145.36 €
- Drop-tech ltd (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €